Core Viewpoint - The company Tongyuan Kang Pharmaceutical-B (02410.HK) announced that its investigational first-class new drug, Tyrosine Kinase Inhibitor (TY-9591), has been proposed for inclusion in the priority review list by the National Medical Products Administration (NMPA) [1] Group 1 - The proposed indication for TY-9591 is for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations, along with central nervous system (CNS) metastases [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 董事會亦已注意到本公司股份價格及成交量近期出現不尋常波動。經作出合理查 詢後，董事會確認，除上文所披露者外，截至本公告日期，其並不知悉導致有關 波動的任何原因，或為避免本公司證券出現虛假市場而須予披露的任何資料，或 根據香港法例第571章證券及期貨條例第XIVA部須予披露的任何內幕消息。 截至本公告日期，董事會確認本集團的業務經營正常穩定，其核心業務進展順 利，並無任何引起董事會和本公司管理層關注的須予披露的重大事項。 1 上市規則第18A.05條規定的警示聲明：無法保證本公司將能最終成功開發及銷售 相關產品。本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 自願公告 甲磺酸艾多替尼片（TY-9591片）擬納入優先審評；及 股價及成交量的不尋常變動 浙江同源康醫藥股份 ...

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has seen a significant stock increase, rising over 10% and currently trading at 13.95 HKD with a transaction volume of 32.66 million HKD, following the announcement of its drug application for priority review [1] Group 1: Company Developments - On January 6, the CDE official website indicated that Tongyuan Kang Pharmaceutical's application for Tyrosine Kinase Inhibitor (TY-9591) is proposed for priority review [1] - The drug is intended for first-line treatment in adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletions (19DEL) or exon 21 (L858R) substitution mutations, along with central nervous system (CNS) metastases [1] - The company previously garnered significant attention at the World Lung Cancer Conference in September, where it presented key Phase II clinical trial results for TY-9591 targeting brain metastases in non-small cell lung cancer [1]

消息面上，1 月 6 日，CDE 官网显示，同源康医药申报的甲磺酸艾多替尼片（TY-9591 片）拟纳入优先 审评，用于具有表皮生长因子受体（EGFR）外显子 19 缺失（19DEL）或外显子 21（L858R）置换突 变，并伴有中枢神经系统（CNS）转移的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者的一线 治疗。值得一提的是，在去年9月份的世界肺癌大会上，同源康医药发布的艾多替尼片针对非小细胞肺 癌脑转移关键Ⅱ期临床试验引起同行高度关注。 智通财经APP获悉，同源康医药-B(02410)涨超10%，截至发稿，涨7.97%，报13.95港元，成交额3266.34 万港元。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 浙江同源康醫藥股份有限公司 (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02410 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 375,457,818 | RMB | | 1 RMB | | 375,457,818 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 375,457,818 | RMB | | 1 RMB | | 375,457,818 | | 2. ...

Group 1 - The top three companies with the highest short-selling ratios are Cheung Kong (00001), CLP Holdings (00002), and Hong Kong and China Gas (00003), all reporting a short-selling ratio of 0.00% [1][2] - The top three companies by short-selling amount are also Cheung Kong (00001), CLP Holdings (00002), and Hong Kong and China Gas (00003), with amounts not specified [1][2] - The companies with the highest deviation values are Energy and Energy Global (01142), Hu Shang Ayi (02589), and China Shipbuilding Defense (00317), with deviation values of -0.41%, -0.41%, and -0.66% respectively [1][2] Group 2 - The top ten short-selling ratios include Cheung Kong (00001), CLP Holdings (00002), and Hong Kong and China Gas (00003), all at 0.00%, with significant negative deviation values [2] - The top ten short-selling amounts also feature Cheung Kong (00001), CLP Holdings (00002), and Hong Kong and China Gas (00003), all at 0.00% short-selling ratio and notable negative deviation values [2] - The top ten companies with the highest deviation values include Energy and Energy Global (01142), Hu Shang Ayi (02589), and China Shipbuilding Defense (00317), with deviation values indicating a decline compared to their average short-selling ratios over the past 30 days [2][3]

Group 1 - The stock price of Tongyuan Kang Pharmaceutical-B (02410) increased by over 6% during trading, with a current price of 13.14 HKD and a trading volume of 29.83 million HKD [1][6] - A clinical trial for the TEAD inhibitor TYK-01054 capsule has been initiated, focusing on its safety, tolerability, pharmacokinetics, and anti-tumor activity in patients with locally advanced or metastatic solid tumors [1][6] - The clinical trial is an I/II phase, open-label, multi-center study, with the registration number CTR20255003, and the first public information date is set for December 26, 2025 [1][6] Group 2 - TYK-01054 capsule is a chemical drug indicated for advanced solid tumors, which are characterized by cancer cells spreading to other parts of the body, with symptoms varying by tumor type, commonly including pain and fatigue [1][6] - Diagnosis of advanced solid tumors relies on imaging examinations and pathological biopsies [1][6]

（文章来源：每日经济新闻） 每经AI快讯，同源康医药-B(02410.HK)一度涨超6%，截至发稿涨4.6%，报13.41港元，成交额2088.14万 港元。 ...

公开资料显示，TYK-01054胶囊为化学药物，适应症为晚期实体瘤。晚期实体瘤指癌细胞已扩散到身体 其他部位的肿瘤，症状因肿瘤类型而异，常见有疼痛、乏力等。诊断依靠影像学检查、病理活检等。 消息面上，药物临床试验登记与信息公示平台数据显示，浙江同源康医药股份有限公司的一项评估 TEAD抑制剂TYK-01054胶囊在局部进展或转移性晚期实体瘤患者中的安全性、耐受性、药代动力学和 抗肿瘤活性的I/II期、开放标签、多中心研究已启动。临床试验登记号为CTR20255003，首次公示信息 日期为2025年12月26日。 智通财经APP获悉，同源康医药-B(02410)现涨超6%，截至发稿，涨4.6%，报13.41港元，成交额2088.14 万港元。 ...

消息面上，药物临床试验登记与信息公示平台数据显示，浙江同源康医药股份有限公司的一项评估 TEAD抑制剂TYK-01054胶囊在局部进展或转移性晚期实体瘤患者中的安全性、耐受性、药代动力学和 抗肿瘤活性的I/II期、开放标签、多中心研究已启动。临床试验登记号为CTR20255003，首次公示信息 日期为2025年12月26日。 公开资料显示，TYK-01054胶囊为化学药物，适应症为晚期实体瘤。晚期实体瘤指癌细胞已扩散到身体 其他部位的肿瘤，症状因肿瘤类型而异，常见有疼痛、乏力等。诊断依靠影像学检查、病理活检等。 同源康医药-B(02410)现涨超6%，截至发稿，涨4.6%，报13.41港元，成交额2088.14万港元。 ...